Albendazole: a new single dose anthelmintic. Study in 1455 patients.
Albendazole has been tested in an open trial conducted in France, seven countries of West-Africa, Martinique and the People's Republic of China in a total of 1455 patients harboring single or mixed infections caused by round-worms, pinworms, hookworms and whipworms. All patients were closely observed before and after treatment for clinical side effects and hematology and clinical chemistry values were done in about 5% of the cases. Fecal samples obtained before and approximately 15, 16 and 17 days after treatment were examined using the Kato test, and when negative, a concentration technic. In case of ancylostomiasis, a coproculture was carried out for species identification. Following a single oral dose, albendazole was highly effective in enterobiasis (100%), ascariasis (89%), ancylostomiasis caused by Necator americanus (88%) and trichuriasis (70%). The drug did not procedure any significant adverse reactions or modifications of the hematological and clinical blood chemistry values and only 6% of the 1455 patients reported minor side effects.
D000293:Adolescent; D000328:Adult; D000354:Africa, Western; D015766:Albendazole; D000871:Anthelmintics / Q000627:therapeutic use*; D001196:Ascariasis / Q000188:drug therapy; D001562:Benzimidazoles / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D002681:China; D002986:Clinical Trials as Topic; D005260:Female; D005602:France; D006801:Humans; D008297:Male; D008395:Martinique; D008875:Middle Aged; D009332:Necatoriasis / Q000188:drug therapy; D009349:Nematode Infections / Q000188:drug therapy*; D010123:Oxyuriasis / Q000188:drug therapy; D014257:Trichuriasis / Q000188:drug therapy
D000871:Anthelmintics; D001562:Benzimidazoles; D015766:Albendazole